MDT-AP-3324
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 10.4
- sex
- M
- new_clusters
- S1
- umap1_2d
- -0.89494033
- umap2_2d
- -11.42111751
- umap1_3d
- -3.837395026
- umap2_3d
- -0.000808392
- umap3_3d
- 5.911628552
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.450
- MYC_TARGETS_V1+0.400
- PROTEIN_SECRETION+0.390
- UV_RESPONSE_DN+0.390
- E2F_TARGETS+0.370
- INTERFERON_GAMMA_RESPONSE+0.370
- G2M_CHECKPOINT+0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.340
- MITOTIC_SPINDLE+0.300
- MYC_TARGETS_V2+0.290
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.240
- APICAL_SURFACE-0.220
- UV_RESPONSE_UP-0.170
- KRAS_SIGNALING_DN-0.160
- PEROXISOME-0.140
- SPERMATOGENESIS-0.130
- CHOLESTEROL_HOMEOSTASIS-0.080
- HEME_METABOLISM-0.080
- ESTROGEN_RESPONSE_LATE-0.060
- XENOBIOTIC_METABOLISM-0.060
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-3069 | Med | Medulloblastoma | 0.871 |
| 2 | SRR934925 | — | — | 0.848 |
| 3 | MDT-AP-3168 | Med | Medulloblastoma | 0.846 |
| 4 | MDT-AP-2865 | Med | Medulloblastoma | 0.834 |
| 5 | SRR934922 | — | — | 0.828 |
| 6 | MDT-AP-3073 | Med | Medulloblastoma | 0.827 |
| 7 | MDT-AP-3337 | Med | Medulloblastoma | 0.826 |
| 8 | SRR934827 | — | — | 0.825 |
| 9 | MDT-AP-3050 | Med | Medulloblastoma | 0.823 |
| 10 | TCGA-BT-A3PJ-01A-21R-A220-07 | — | — | 0.822 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.450 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.390 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.390 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.370 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.370 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.350 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.340 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.290 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.280 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.280 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.250 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.240 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.240 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.210 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| COMPLEMENT | 0.190 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.180 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.160 | Inavolisib | — uncovered |